Blau Farmacêutica S.A (BLAU3) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Blau Farmacêutica S.A stock BRL 21.87, price BRL 8.96, upside +144.1%, quality 43 out of 100. Rating: strongly undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range R$6.25 – R$467,658 · fair‑value band R$16.28 – R$27.94 · the R$8.96 price screens below the R$21.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Blau Farmacêutica in your weekly email
Every Wednesday you see whether Blau Farmacêutica is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Blau Farmacêutica S.A., a pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its products cover various areas, such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology.
Show moreShow less
The company offers uterine stimulator, antirheumatic, anaesthetics, antibiotics, feminine health care, biopharmaceuticals, oncologicals, hospital products, antivirals and antiretrovirals, biológicos, acid pump inhibitor, hemoderivatives, antithrombotic, and thrombolytics products.
Blau Farmacêutica S.A. was incorporated in 1987 and is headquartered in Cotia, Brazil.
Stock analysis
Blau Farmacêutica S.A (BLAU3) currently trades at R$8.96, while our model-based Fair Value estimate is R$21.87, implying the stock looks roughly 59% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of R$27.67 per share, and 11 of the 16 models we run sit above the R$8.96 price.
Bear case: the Asset-Based group reads lowest at R$2.31, and 5 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: R$16.28 (bear) to R$27.94 (bull), the price of R$8.96 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Blau Farmacêutica S.A reported revenue of R$1.7B in FY2025 versus R$1.4B in FY2021, a compound +5.6%/yr. Reported net income was R$295M in FY2025, compounding −2.4%/yr from FY2021.
Key figures
Market cap R$2.1B (≈ $379M) Small · P/E ratio 6.9 · P/S ratio 1.20 · EPS (TTM) R$1.29 · Dividend yield 0.0% · Net margin 17.3% · Return on equity 10.3% · Return on assets (EBIT) 12.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 144%, BLAU3 screens cheaper than that median.
Fair Value models
BearR$16.28Fair Value R$21.87BullR$27.94
Price R$8.96 · Upside +144.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (R$1.10 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.42/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−3.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
Start year 2020 (pandemic). Over 10 years: +16.1% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in BRL ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in BRL: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−7.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−7.5% vs 23.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.33% → 19%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score43 · Below median
Fair Value upside+144.1% · Top 25%
Profitability
Return on equity (12 months)10.3% · Above median
Return on assets8.1% · Top 25%
Net margin (12 months)13.1% · Above median
Operating margin (12 months)17.1% · Above median
Growth and dividend
Revenue growth (quarter YoY)4.7% · Below median
Dividend yield (12 months)0.0% · Bottom 25%
Balance sheet
Debt / equity0.13× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Blau Farmacêutica S.A (BLAU3) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of R$21.87 versus a price of R$8.96, about +144% upside (undervalued).
What is the fair value of BLAU3?
Our model-based fair value for Blau Farmacêutica S.A is R$21.87 (as of Nov 8, 2026), built from audited fundamentals. The current price: R$8.96.
What is the quality score of BLAU3?
Blau Farmacêutica S.A has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Blau Farmacêutica S.A (BLAU3)?
Our model-based price target is the fair value of R$21.87 (as of Nov 8, 2026) from 16 valuation models. Cautious scenario R$16.28, optimistic scenario R$27.94. It is a calculation from audited fundamentals, not an analyst target.
What is the Blau Farmacêutica S.A stock forecast for 2026?
Our models put fair value at R$21.87, about +144% upside versus a price of R$8.96 (undervalued). Cautious scenario R$16.28, optimistic scenario R$27.94. The calculation is refreshed regularly with new filings.
What is the revenue of Blau Farmacêutica S.A (BLAU3)?
Blau Farmacêutica S.A reported trailing-twelve-month revenue of about R$1.8B (latest available figure, as of Nov 8, 2026).
Does Blau Farmacêutica S.A pay a dividend?
Blau Farmacêutica S.A currently shows a dividend yield of 0.02% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Blau Farmacêutica S.A (BLAU3) and when is the ex-dividend date?
Blau Farmacêutica S.A pays a dividend of R$0.002 per share a year, a dividend yield of 0.0%. The last ex-dividend date was Sep 30, 2026. A dividend has been paid every year since at least 2021. The payout ratio is 0.2% of earnings. Our assessment: Token dividend. At a yield of 0.0% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.0% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Blau Farmacêutica S.A (BLAU3)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Blau Farmacêutica S.A it is R$21.87 per share (as of Nov 8, 2026), against a price of R$8.96. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Blau Farmacêutica S.A stock overvalued or undervalued in 2026?
As of Nov 8, 2026, BLAU3 trades below its calculated fair value: price R$8.96, fair value R$21.87, a gap of about +144% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BLAU3?
No. The price is what the market pays today (R$8.96); the fair value is what the company's own numbers justify (R$21.87). For Blau Farmacêutica S.A the two are R$12.91 per share apart. That gap is exactly why we show both numbers side by side.
How much is Blau Farmacêutica S.A worth?
The market values Blau Farmacêutica S.A at about R$2.1B (market capitalisation, as of Nov 8, 2026). Per share that is R$8.96; our models calculate a fair value of R$21.87 per share.
What do the bullish and bearish scenarios say about BLAU3?
Our models span a range for Blau Farmacêutica S.A: cautious scenario R$16.28, base R$21.87, optimistic R$27.94 per share (as of Nov 8, 2026, price R$8.96). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BLAU3?
Blau Farmacêutica S.A trades at a price-to-earnings ratio of 6.9 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of R$21.87 is built from several models across several years. Other multiples: P/B 0.9, P/S 1.2, EV/EBITDA 6.5.
How solid is the balance sheet of Blau Farmacêutica S.A (BLAU3)?
Balance-sheet figures for Blau Farmacêutica S.A (as of Nov 8, 2026): return on equity 10.3%, debt of 0.13 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is BLAU3 from its 52-week high?
Blau Farmacêutica S.A trades at R$8.96, about 35% below its 52-week high of R$13.70 and 7% above the low of R$8.35 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of R$21.87 is for.
Which stocks are comparable to Blau Farmacêutica S.A?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Blau Farmacêutica S.A stock attractive at the current price?
The data as of Nov 8, 2026: price R$8.96, calculated fair value R$21.87 (+144%), Quality Score 43/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BLAU3 calculated?
We run Blau Farmacêutica S.A through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of R$21.87 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Blau Farmacêutica S.A currently trades 59% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Blau Farmacêutica S.A (BLAU3)?
The closing price on Nov 6, 2026 was R$8.96. Our model-based fair value is R$21.87, about +144% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Blau Farmacêutica S.A right now?
The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (R$16.28). The market is more pessimistic than our downside scenario.
Where does the earnings growth of Blau Farmacêutica S.A (BLAU3) come from?
Earnings per share at Blau Farmacêutica S.A grew +26.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +14.7 %, EBIT margin +2.0 %, tax rate +0.2 %, residual (interest, one-offs) +7.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Blau Farmacêutica S.A
How large is the market capitalisation of Blau Farmacêutica S.A (BLAU3)?
The market capitalisation of Blau Farmacêutica S.A is R$2.1B (≈ $379M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Blau Farmacêutica S.A (BLAU3)?
The price-to-sales ratio of Blau Farmacêutica S.A is 1.20 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Blau Farmacêutica S.A (BLAU3)?
Earnings per share at Blau Farmacêutica S.A are R$1.29 (price ÷ EPS = P/E 6.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Blau Farmacêutica S.A (BLAU3)?
The dividend yield of Blau Farmacêutica S.A is 0.0% (payout 0.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Blau Farmacêutica S.A (BLAU3)?
The net margin of Blau Farmacêutica S.A is 17.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Blau Farmacêutica S.A (BLAU3)?
The return on equity (ROE) of Blau Farmacêutica S.A is 10.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Blau Farmacêutica S.A (BLAU3)?
On an EBIT basis the return on assets of Blau Farmacêutica S.A is 12.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Blau Farmacêutica S.A (BLAU3)?
The operating margin of Blau Farmacêutica S.A is 17.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Blau Farmacêutica S.A (BLAU3)?
Revenue at Blau Farmacêutica S.A is growing +4.7% versus a year earlier (3y avg +6.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Blau Farmacêutica S.A (BLAU3)?
Earnings per share at Blau Farmacêutica S.A are growing −14.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Blau Farmacêutica S.A (BLAU3) generate?
The free cash flow of Blau Farmacêutica S.A is −R$39.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Blau Farmacêutica S.A (BLAU3) carry?
The net debt of Blau Farmacêutica S.A is R$554M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Blau Farmacêutica S.A in the live analysis
One click puts Blau Farmacêutica S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026